Abcam, ab263431, Human ZCCHC2 knockout A549 cell lysate

Size: 1Kit
ZCCHC2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ZCCHC2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The zinc finger CCHC domain-containing protein 2 also known as ZCCHC2 functions mechanically as an RNA-binding protein. It plays a role in RNA metabolic processes. ZCCHC2 is approximately 90 kDa in mass and includes several zinc finger motifs that are important for its interaction with RNA. It is expressed highly in the nucleus of cells across various tissues with notable levels in the brain and other central nervous system structures. This indicates its involvement in regulating RNA under specific physiological conditions.
Biological function summary
ZCCHC2 interacts with the cellular machinery involved in RNA splicing and processing. It is part of ribonucleoprotein complexes that facilitate these functions. This protein assists in modulating RNA stability and contributes to the precise processing required for mature RNA molecules. These activities are important for maintaining proper gene expression by ensuring that RNA transcripts are accurately produced and modified before translation occurs.
Pathways
ZCCHC2 plays a role in RNA processing and degradation pathways. It acts within the spliceosomal complex aiding in the proper removal of introns from pre-mRNA. ZCCHC2 interacts with other proteins such as components of the Human spliceosome which include splicing factors that orchestrate the splicing process. It also connects with pathways linked to RNA surveillance mechanisms where it helps in quality control of RNA transcripts.
ZCCHC2 has connections to neurological conditions and cancer. Abnormal expression levels or mutations in ZCCHC2 may relate to altered splicing activities leading to neurodevelopmental disorders. Additionally its dysregulation might contribute to the genesis of certain cancers through disrupted RNA processing. Proteins like spliceosomal components and RNA-binding proteins are usually involved in such diseases highlighting the importance of balanced ZCCHC2 function for cellular health.